A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB

NCT ID: NCT06122454

Last Updated: 2023-11-08

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-10
• Study Completion Date: 2024-12-30

Brief Summary

The goal of this a clinical trial is to learn about the efficacy，safety and Pharmacokinetics of Hepenofovir Fumarate Tablets（HTS） in patients with CHB. The main questions it aims to answer are：

1. Evaluate the efficacy and safety of multiple doses of continuous administration of HTS in patients with chronic hepatitis B, and compare it with Tenofovir alafenamide Fumarate tablets（TAF）.

2. To evaluate the pharmacokinetic characteristics of HTS in patients with chronic hepatitis B after multiple oral administration.

3. To evaluate the pharmacodynamic changes of HTS in patients with chronic hepatitis B after multiple consecutive administrations, and compare it with TAF.

Positive control drug：Tenofovir alafenamide Fumarate tablets（25mg/d） Test drug：Hepenofovir Fumarate Tablets（10mg/d、20mg/d、40mg/qod） Test process：This study was divided into 4 groups, with the specific list shown below. The initial plan was to include 12 subjects in each group, stratified by HBeAg status, with 4 subjects negative for HBeAg and 8 subjects positive for HBeAg. A total of 48 subjects were included in this trial, and they were randomly assigned to multiple doses at a ratio of 1:1:1:1. The dosing period was 24 weeks. However, after enrolling 37 subjects (29 positive for HBeAg and 8 negative for HBeAg), the protocol was adjusted (V4.0): the remaining 11 subjects would be included, all of whom were over 30 years old with ALT < ULN and met all the inclusion criteria but none of the exclusion criteria. The random assignment was: 7 subjects positive for HBeAg were randomly assigned to HTS 10mg/day, 20mg/day, 40mg/qod and TAF 25mg/day groups at a ratio of 2:2:2:1; and 4 subjects negative for HBeAg were randomly assigned to HTS 10mg/day, 20mg/day, 40mg/qod and TAF 25mg/day groups at a ratio of 1:1:1:1.

Conditions

Efficacy; Safety; Pharmacokinetics

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Tenofovir alafenamide Fumarate tablets

TAF is taken orally under postprandial conditions, and subjects begin eating breakfast within 30 minutes of taking the drug. The 25mgQD group is given a single daily dose for 24 consecutive weeks, and continues to take the drug for 48 weeks after completing the 24-week treatment.

Group Type: ACTIVE_COMPARATOR

Hepenofovir Fumarate Tablets

Intervention Type: DRUG

Each subject received multiple doses of the test drug/control drug and completed safety, efficacy, and PK evaluations

Hepenofovir Fumarate Tablets

After taking HTS tablets orally under postprandial conditions, subjects began to eat breakfast within 30 minutes before taking the drug. The 10mgQD and 20mgQD dose groups were administered once daily for 24 consecutive weeks, and continued to be administered for 48 weeks after completing the 24-week treatment. The 40mgQOD group was administered once every other day for 24 weeks, and continued to be administered for 48 weeks after completing the 24-week treatment.

Group Type: EXPERIMENTAL

Hepenofovir Fumarate Tablets

Intervention Type: DRUG

Each subject received multiple doses of the test drug/control drug and completed safety, efficacy, and PK evaluations

Interventions

Hepenofovir Fumarate Tablets

Each subject received multiple doses of the test drug/control drug and completed safety, efficacy, and PK evaluations

Intervention Type: DRUG

Other Intervention Names

Tenofovir alafenamide Fumarate tablets

Eligibility Criteria

Inclusion Criteria

1. Subjects voluntarily sign the informed consent form.

2. Subjects (including partners) are willing to have no plans for pregnancy from the time of screening to 3 months after the last administration of the study drug and ensure appropriate contraception measures are taken.

3. Male or female subjects (including boundary values) between 18-65 years of age, regardless of gender.

4. Body mass index (BMI) between 18.0-32.0 kg/m2 (including critical values), where BMI = body weight (kg) / height2 (m2).

5. Evidence (including but not limited to outpatient/inpatient medical records/laboratory reports, etc.) to prove a history of positive hepatitis B surface antigen (HBsAg) or positive HBV DNA for at least 6 months at the time of screening, or negative HBcAb IgM and positive HBsAg at the time of screening, or histological examination of liver tissue showing chronic hepatitis B infection.

6. HBeAg-positive patients with HBV DNA ≥ 2.0×104 IU/mL and HBeAg-negative patients with HBV DNA ≥ 2.0×103 IU/mL at the time of screening.

7. Subjects with ALT between 1.2×ULN and 10×ULN within 7 days of screening, or subjects over 30 years of age with ALT less than 1.2×ULN; total bilirubin (TBIL) ≤ 2×ULN;

8. Creatinine clearance rate ≥ 70 mL/min [calculation formula: Ccr: (140-age)×weight (kg) / (0.818×Scr) (μmol/L), female×0.85];

9. Subjects who have not used anti-HBV nucleotide/nucleoside therapy, interferon therapy, or immunomodulators within the previous 6 months prior to screening;

10. Subjects who fully understand the trial process, possible adverse reactions, and can complete the trial according to the protocol plan.

Exclusion Criteria

1. Subjects with a history of allergies to HTS and TAF, or any other similar drugs, metabolites, or excipients;

2. Subjects who participated in other drug clinical trials within one month prior to the study;

3. Subjects with positive results for hepatitis C antibody, hepatitis C core antigen, HIV antibody, or syphilis antibody screen (if syphilis antibody positive, additional rapid plasma reagin test (RPR) is required, and the investigator should use the results to determine if there is a positive reaction);

4. Subjects with any known disorders in glutathione metabolism (e.g., glutathione deficiency anemia, glutathioneemia), or subjects who require high doses of acetaminophen/Tylenol® (>1 g/day);

5. Subjects with a QTcF interval >470 ms (men) or >480 ms (women) on electrocardiogram at the time of screening (corrected using Fridericia's formula), or any other electrocardiogram abnormalities deemed to be clinically significant by the investigator;

6. Subjects with a history of persistent substance abuse in the past or recent times;

7. People who smoke and drink excessively (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of hard liquor, or 1 glass of wine; smoking ≥ 5 cigarettes per day);

8. People with decompensated liver disease (Child-Pugh score of B or C), including but not limited to: hepatic encephalopathy, hepatorenal syndrome, variceal bleeding, ascites, or a history of HCC;

9. People with an alpha-fetoprotein (AFP) level > 50 ng/mL at the time of screening, or with imaging suggesting the possibility of malignant liver lesions;

10. People with a history of malignancy within the past 5 years [exceptions: surgically resected and completely cured specific cancers (such as skin basal cell carcinoma or squamous cell carcinoma) or cervical intraepithelial neoplasia];

11. People with a history of organ transplantation or bone marrow transplantation;

12. People who require long-term use of immunosuppressants or drugs with a high risk of liver or kidney toxicity (such as dapsone, erythromycin, fluconazole, ketoconazole, rifampicin, etc.);

13. Pregnant or breastfeeding women or with positive serum pregnancy results;

14. People with other significant liver diseases in addition to hepatitis B, including but not limited to chronic alcoholic hepatitis, drug-induced hepatitis, autoimmune liver disease, etc.

15. Other serious diseases of important organs include but are not limited to definite medical history of nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and skeletal muscle system (such as poorly controlled diabetes (type 1 diabetes or uncontrolled type 2 diabetes (HbA1c≥9.0%)), hypertension that is not well-controlled after medication (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg), etc.), which the investigator believes makes the subject unsuitable for participation in this study;

16. A history of swallowing difficulties or any gastrointestinal diseases that affect drug absorption;

17. Donating blood or losing blood >500 mL within 2 months prior to screening, or donating plasma within 14 days prior to screening;

18. Any significant clinical and laboratory abnormalities (neutrophil count <1.2×109/L during screening; platelet count <80×109/L during screening; hemoglobin <90g/L during screening; international normalized ratio (INR) >1.5 during screening), or investigator believes it affects safety evaluation.

19. Screening urine test: proteinuria > 1+;

20. Positive urine drug screen (morphine, cannabis) or positive breath alcohol test;

21. Subjects who may not be able to complete the trial for other reasons or who the investigator believes should not be included.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The First Hospital of Jilin University

OTHER

Sponsor Role: collaborator

Xi'an Xintong Pharmaceutical Research Co.,Ltd.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

The First Hospital of Jilin University

Jilin, Changchun, China

Site Status: RECRUITING

Countries

China

Central Contacts

Ding Yanhua, Master

Role: CONTACT

1023307193@qq.com

18743062721

Facility Contacts

Ding Yanhua, master

Role: primary

Other Identifiers

XAXT-2022-001

Identifier Type: -

Identifier Source: org_study_id